Insider Selling: Bicycle Therapeutics plc (NASDAQ:BCYC) COO Sells 4,578 Shares of Stock

Bicycle Therapeutics plc (NASDAQ:BCYC) COO Alistair Milnes sold 4,578 shares of the company’s stock in a transaction on Thursday, January 2nd. The shares were sold at an average price of $14.09, for a total value of $64,504.02. Following the completion of the transaction, the chief operating officer now directly owns 100,724 shares in the company, valued at $1,419,201.16. This trade represents a 4.35 % decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link.

Bicycle Therapeutics Stock Down 6.4 %

Bicycle Therapeutics stock opened at $14.17 on Thursday. Bicycle Therapeutics plc has a twelve month low of $12.17 and a twelve month high of $28.67. The business has a fifty day moving average of $19.09 and a two-hundred day moving average of $21.82. The firm has a market cap of $978.38 million, a P/E ratio of -4.31 and a beta of 0.92.

Bicycle Therapeutics (NASDAQ:BCYC) last issued its quarterly earnings data on Thursday, October 31st. The company reported ($0.74) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.78) by $0.04. The company had revenue of $2.68 million for the quarter, compared to the consensus estimate of $6.82 million. Bicycle Therapeutics had a negative return on equity of 27.35% and a negative net margin of 450.64%. The firm’s revenue for the quarter was down 50.0% compared to the same quarter last year. During the same quarter last year, the company earned ($1.26) earnings per share. Equities analysts expect that Bicycle Therapeutics plc will post -3.05 earnings per share for the current year.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently modified their holdings of the company. Assetmark Inc. acquired a new stake in Bicycle Therapeutics in the third quarter valued at approximately $34,000. GAMMA Investing LLC lifted its holdings in shares of Bicycle Therapeutics by 105.1% during the 3rd quarter. GAMMA Investing LLC now owns 2,026 shares of the company’s stock valued at $46,000 after purchasing an additional 1,038 shares during the last quarter. China Universal Asset Management Co. Ltd. grew its stake in Bicycle Therapeutics by 69.1% during the 3rd quarter. China Universal Asset Management Co. Ltd. now owns 7,138 shares of the company’s stock worth $162,000 after buying an additional 2,918 shares during the last quarter. JPMorgan Chase & Co. increased its position in Bicycle Therapeutics by 26.8% during the 3rd quarter. JPMorgan Chase & Co. now owns 8,424 shares of the company’s stock valued at $191,000 after buying an additional 1,782 shares in the last quarter. Finally, XTX Topco Ltd purchased a new stake in Bicycle Therapeutics in the second quarter valued at about $206,000. Hedge funds and other institutional investors own 86.15% of the company’s stock.

Analyst Upgrades and Downgrades

BCYC has been the topic of a number of research analyst reports. Royal Bank of Canada restated an “outperform” rating and issued a $35.00 price target on shares of Bicycle Therapeutics in a report on Friday, November 1st. Stephens started coverage on shares of Bicycle Therapeutics in a research report on Friday, November 8th. They set an “equal weight” rating and a $25.00 target price on the stock. JMP Securities lowered their price target on Bicycle Therapeutics from $32.00 to $26.00 and set a “market outperform” rating for the company in a report on Wednesday, December 18th. HC Wainwright decreased their target price on Bicycle Therapeutics from $55.00 to $33.00 and set a “buy” rating for the company in a research report on Monday, December 16th. Finally, B. Riley dropped their price target on Bicycle Therapeutics from $28.00 to $17.00 and set a “neutral” rating on the stock in a research report on Friday, December 13th. Two equities research analysts have rated the stock with a hold rating and seven have assigned a buy rating to the company. According to data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and an average price target of $35.25.

Bicycle Therapeutics Company Profile

Bicycle Therapeutics plc, a clinical-stage biopharmaceutical company, develops a class of medicines for diseases that are underserved by existing therapeutics in the United States and the United Kingdom. Its product pipeline comprising BT8009, a bicycle toxin conjugate (BTC) which is in phase I/II/III clinical trial for the treatment of high nectin-4 expressing tumors; BT5528, a BTC which is in phase I/II clinical trial for the treatment of Ephrin type A receptor 2 expressing tumor; BT7480, a Bicycle TICA molecule which is in phase I/II targeting Nectin-4 and agonizing CD137; and BT7455, a Bicycle TICA molecule targeting Ephrin type A receptor 2 and CD137 and is in preclinical trial.